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Abstract
Background Since 2010, several new treatments for pros-
tate cancer (PCa), which have entered the US market, are
poised to have an impact on treatment approaches; however,
there is a paucity of evidence with respect to treatment
patterns and costs. As new treatment patterns emerge, it will
be imperative to understand treatment patterns and costs of
care prior to the advent of novel treatments.
Objective As the PCa treatment landscape is evolving,
this study sought to compare the hospital-based utilization
and costs in two cohorts of patients with PCa: patients with
bone metastases (w/BM) and patients without bone
metastases (w/oBM). Comparisons were also made for
patients with inpatient versus outpatient encounters.
Methods Patients in the Premier Perspective Database, a
US hospital database, between January 2006 and December
2010, treated in an inpatient or outpatient setting for PCa
(International Classification of Diseases, 9th Revision
[ICD-9] diagnosis codes 185, 233.4) were included.
Patients were required to be C40 years of age with no
additional cancers. Patients were put into cohorts on the
basis of the presence of bone metastases (ICD-9 code 198.5
or use of zoledronic acid or pamidronate disodium). Uti-
lization of PCa-related treatments was compared, control-
ling for age, race, hospital type, payer type, bed size, and
admission source and type. Differences in treatments were
assessed utilizing logistic regression, while differences in
costs were analyzed using gamma-distributed generalized
linear models with a log-link function. All costs are
reported in US$ 2010.
Previous presentation: Parts of these results were presented at ISPOR
International Conference in Washington, DC, in May 2012 (Poster
#PCN51). This paper expands upon and adds to that analysis.
Electronic supplementary material The online version of this
article (doi:10.1007/s40258-014-0101-1) contains supplementary
material, which is available to authorized users.
B. Seal
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
e-mail: brian.seal@bayer.com
S. D. Sullivan
University of Washington, Seattle, WA, USA
e-mail: sdsull@u.washington.edu
S. D. Ramsey
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
e-mail: sramsey@fhcrc.org
C. V. Asche
University of Illinois College of Medicine, Peoria, IL, USA
e-mail: cva@uic.edu
K. Shermock





E. A. Zagadailov  E. Farrelly  M. Eaddy (&)






Appl Health Econ Health Policy (2014) 12:547–557
DOI 10.1007/s40258-014-0101-1
Results There were 23,747 hospitalizations for men
w/BM (13,716 inpatient; 10,031 outpatient) and 187,708
hospitalizations (74,435 inpatient; 113,258 outpatient) for
men w/oBM. The mean length of stay for men w/BM was
4 days compared with 2 days for men w/oBM
(P \ 0.0001). Overall, the mean cost per encounter was
US$9,728 in men with w/BM and US$7,405 in men
w/oBM (P = 0.0006). For inpatient stays, the mean cost
per encounter was US$14,145 for men w/BM and
US$11,944 for men w/oBM. For outpatient visits, the mean
cost per encounter was US$3,688 for men w/BM and
US$4,422 for men w/oBM. Men w/BM received hormone
therapy (44.3 %) and secondary hormone therapy (46.4 %)
most often, while men w/oBM received radiation (48.8 %)
and surgery (31.9 %) most often.
Conclusion Costs and utilization of PCa-related treat-
ments vary on the basis of the presence of metastases and
treatment setting (inpatient vs. outpatient).
Key Points for Decision Makers
Inpatient hospital care plays a significant role in men
with prostate cancer with bone metastasis.
This study highlights to decision makers the
differences in the cost of treating men with prostate
cancer with and without bone metastases and
provides a context for future trends, given new
therapeutic options.
1 Introduction
Prostate cancer (PCa) is the most commonly diagnosed
cancer in men in the USA, and is ranked the second most
common cancer in terms of cancer-related mortality [1]. It
is estimated that more than 241,700 new cases of PCa will
be diagnosed in 2012 (29 % of all cancer diagnoses),
resulting in more than 28,170 PCa-related deaths (9 % of
all cancer deaths) in the USA [2].
Approximately 95 % of patients with PCa are diagnosed
when asymptomatic in early disease stages. These patients
have a 5-year survival rate of 100 % [3]. Since early dis-
ease is considered curative, its management is individual-
ized [4]. Therapy options include surgery such as radical
prostatectomy (RP); radiation therapy (RT), mainly exter-
nal beam RT and brachytherapy; or watchful waiting
(delaying therapy until progressive or symptomatic dis-
ease) [4]. In addition, androgen deprivation therapy (ADT)
may be combined with RT in patients who have a high risk
for recurrence [4].
In contrast, approximately 4 % of patients have meta-
static prostate cancer (MPC) [3] upon diagnosis. These
patients have an unfavorable 5-year survival rate of about
28 % [3, 5]. The treatment of advanced PCa is palliative;
the first-line treatment option is ADT [4]. The majority of
MPC patients subsequently develop castration-resistant
prostate cancer (CRPC), defined as successive prostate-
specific antigen (PSA) increases and/or disease progression
despite castrate testosterone levels [6, 7]. Salvage treatment
options for CRPC include enrollment in a clinical trial,
secondary hormonal therapy (abiraterone acetate and en-
zalutamide), immunotherapy (sipuleucel-T), and chemo-
therapy (docetaxel and cabazitaxel) [4].
These salvage therapies have shown substantial survival
gains in post-docetaxel patients with CRPC and bone
metastases, ranging from 2.4-4.8 months for cabazitaxel [8],
abiraterone [9], and enzalutamide [10] in the symptomatic
population and 4.1 months for sipuleucel-T in the asymp-
tomatic/minimally symptomatic population [11]. Abirater-
one has also shown an overall survival (OS) benefit in pre-
docetaxel patients with CRCP and bone metastases on the
basis of the interim results from a phase III study [12].
However, these survival benefits come at a considerable
price. For example, the cost of 3 cycles of sipuleucel-T,
based on the wholesale acquisition cost published in Red
Book, is an estimated US$93,000, while secondary hor-
monal therapies, such as prednisone, are available generi-
cally and are relatively inexpensive for the treatment of
symptomatic patients with CRPC [13]. For comparison, the
cost for 6 cycles of docetaxel is over US$14,000, and for
cabazitaxel, over US$38,000 [13]. These costs will increase
further when these new agents are incorporated into earlier
lines of therapy, as these new agents are expected to have
larger survival gains in the less pre-treated cohort [6].
Bone is the most common metastatic site specific to
PCa-related metastases. The majority of patients
(80–90 %) with CRPC have osteoblastic lesions and, less
frequently, osteolytic lesions [14, 15]. As a consequence,
skeletal-related events (SREs) such as fractures and bone
pain develop in these patients, who subsequently require
RT or surgery [16].
The use of bone-targeting agents (e.g., zoledronic acid,
denosumab) is supported to prevent or delay PCa-associ-
ated SREs [4]. RT is regarded as a palliative intervention
for painful bone metastases [4, 17]. Radiopharmaceuticals
are recommended for patients with multifocal bone pain,
particularly if they are no longer eligible for chemotherapy
[18]. The two most commonly used radiopharmaceuticals
for PCa, strontrium-89 (89Sr) and samarium-153 (153Sm),
are classified as b-emitting agents [19]. Unfortunately, both
agents can cause substantial myelosuppression, thus pro-
hibiting their use in patients with inadequate bone marrow
function.
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Radium-223, a novel a-emitting radiopharmaceutical,
targets bone metastases with high-energy, short-range
irradiation, thus preserving bone marrow and limiting
penetration to adjacent tissues [20]. Radium-223 has been
shown to delay the time to first on-study SRE and improve
OS [21]. Enzalutamide, an androgen receptor-signaling
inhibitor, has also demonstrated benefits in SREs and OS
outcomes in patients with bone metastases [22]. Radium-
223 was recently approved by the US Food and Drug
Administration for the treatment of patients with CRPC
with symptomatic bone metastases and no known visceral
metastases, and enzalutamide was approved for the treat-
ment of CRPC post-docetaxel.
A growing body of clinical evidence in support of highly
effective agents in PCa may lead to a trend in multimodal
therapy, particularly with bone-targeted agents. In
advanced PCa, healthcare decision makers can expect a
considerable component of care to be provided in the
inpatient and outpatient hospital settings. Given the
changing landscape of PCa treatment, this study sought to
provide a unique and informative perspective by capturing
the current level of utilization and costs associated with
bone metastases (w/BM) compared with those in the
absence of bone metastases (without [w/oBM]) in the
inpatient and outpatient settings.
2 Methods
2.1 Data Source
Hospital claims data from the Premier Perspective Data-
base were used to conduct the analyses. This database is
the largest hospital database in the USA for determining
hospital quality benchmarking and contains linked, de-
identified inpatient medical, pharmacy, and billing data
from more than 500 geographically dispersed acute care
hospitals. Participating hospitals represent all regions of the
USA, including predominantly small- to medium-sized
non-teaching facilities serving largely urban populations.
The database includes information regarding all hospital-
based encounters, including inpatient stays and outpatient
visits. The database also contains a date-stamped log of all
billed items (including medications, laboratory and diag-
nostic services), as well as primary and secondary diag-
noses for each patient.
2.2 Sample Selection
Patients diagnosed with PCa (International Classification of
Diseases, 9th Revision [ICD-9] diagnosis codes 185.xx,
233.4) and receiving hospital-based services between 2006
and 2010 were eligible for study inclusion. Patients were
required to be C40 years old and to have received C1 PCa-
related treatment during an encounter. PCa treatment was
defined as the presence of a code or claim for prostate
surgery, RT, chemotherapy, hormonal therapy, radiophar-
maceuticals, or other treatments for PCa. Other treatments
for PCa were defined as pharmacotherapy treatments used
to treat PCa that are not considered chemotherapy or pri-
mary hormone therapy, such as ketoconazole or
corticosteroids.
Patients diagnosed with a cancer other than PCa were
excluded (ICD-9 140.xx–172.xx; 174.xx–184.xx; 186.xx;
187.xx; 189.xx–195.xx; and 199.xx–208.xx). Since
patients with PCa may have other distant metastases,
patients with a diagnosis of 198.xx (secondary malignant
neoplasm of other specified sites) who also had a diagnosis
of PCa were not excluded. Patients meeting all criteria
were then placed into the two cohorts on the basis of
diagnosis codes (ICD-9 code 198.5) or medications
(zoledronic acid or pamidronate disodium) indicative of
bone metastases.
2.3 Analysis of Outcomes
The primary variables of interest were treatments utilized,
the corresponding costs of treatments per encounter, and
length of stay (LOS). Costs were initially aggregated by the
department billing for services in order to provide a com-
prehensive description of where they were incurred during
treatment. Component costs for PCa-related treatments
were presented after an independent review of detailed cost
estimates by a radiation oncologist. Specifically, the cor-
responding types and costs of chemotherapy, surgery, RT,
or nuclear medicine were evaluated. Hormonal therapy was
also evaluated and separated into two categories: primary
(5a-reductase inhibitors, antiandrogens, and gonadotropin-
releasing hormones) and secondary (steroids) hormonal
therapy.
Descriptive summary statistics were constructed as fre-
quencies and proportions for categorical data and means
for continuous variables. Differences in baseline demo-
graphics between patients w/BM and w/oBM were asses-
sed using chi-square tests for categorical variables and
t tests for continuous variables. Differences in the per-
centage of treatments used were assessed utilizing logistic
regression, while differences in costs were analyzed using
gamma-distributed generalized linear models with a log-
link function. All costs are reported in US$ 2010 and
adjusted to 2010 dollars using the medical care component
of the Consumer Price Index. Statistical analyses were
conducted in SAS version 9.2.1 (SAS Business Analytics,
Cary, NC, USA), with an a priori significance level of
a = 0.05. Multivariate analyses of costs and LOS con-
trolled for differences in age, race, payer type, region,
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hospital type, bed size, and admission source. Additional




There were 755,375 hospital-based encounters in patients
with a diagnosis of PCa. After exclusion criteria were
applied (cancer diagnosis other than PCa 4.1 %;\40 years
old 0.11 %; female 0.04 %; encounter not associated with
PCa-related treatment 71 %), the final sample included
211,440 encounters associated with C1 PCa-related treat-
ment. These encounters represented 88,151 inpatient stays
and 123,289 hospital-based outpatient visits.
There were 23,747 encounters (11.23 %) for N = 11,769
men w/BM and 187,693 encounters (88.77 %) for
N = 109,675 men w/oBM. The majority of the encounters
w/BM (78 %) were associated with a diagnosis code (ICD-9
code 198.5); however, 7 % of encounters w/BM were
associated with the use of zoledronic acid or pamidronate
disodium, and the remaining 15 % of encounters were
associated with both. The mean age of men w/BM was
73 years versus 69 years for men w/oBM and was signifi-
cantly higher (P \ 0.0001) (Table 1). Two-thirds of
encounters were in Caucasian men (w/oBM 65.7 %; w/BM
62 %), while African American men represented approxi-
mately 10 %. For both groups, the majority of encounters
took place in urban non-teaching hospitals (average bed size
201–400) (Table 1).
Most encounters for men w/oBM occurred in an out-
patient setting (60.3 %), while most encounters for men
w/BM occurred in an inpatient setting (57.8 %). In both
groups, the most common encounters were elective-type
admissions (73.2 % w/oBM and 40.9 % w/BM) (Table 1).
However, in men w/BM, a significantly higher
(P \ 0.0001) number of encounters were emergency
department (38.6 vs. 9.5 %) and urgent admissions (12.4
vs. 5.1 %).
3.2 Treatment Utilization
On average, LOS was 4 days among encounters for men
w/BM versus 2 days for men w/oBM (P \ 0.0001). The
longer LOS across all encounters is consistent with the
higher proportion of men w/BM that had inpatient stays
versus hospital-based outpatient visits. When evaluating
inpatient hospitalizations, encounters for men w/BM
averaged 3 days longer LOS compared with men w/oBM
(7 vs. 4 days). The most common treatment provided for
men w/BM was hormonal therapy (primary and
secondary). The rates of both primary (44 %) and sec-
ondary hormonal therapy (46 %) were significantly higher
(P \ 0.0001) in men w/BM than in men w/oBM (16 and
19 %, respectively) (Fig. 1).
Nearly half of encounters for men w/oBM were asso-
ciated with radiation (49 %), which was significantly
higher (P \ 0.0001) than for men w/BM (24 %) (Fig. 1).
These encounters were more commonly associated with
outpatient visits (79.5 %) than inpatient stays (1.9 %)
(Figs. 2, 3) and were most often brachytherapy related.
Overall, very few patients used nuclear medicine; however,
the use of nuclear medicine-related PCa treatments was
significantly higher (P \ 0.0001) in patients w/oBM
(5.2 %) than in those with w/BM (1.2 %) (Fig. 1). In an
inpatient setting, patients w/oBM received surgery in two
of every three hospital stays (66 %), making surgery the
most common procedure in men w/oBM. Furthermore, RP
(22.9 %) and transurethral resection of the prostate (TURP)
(4.1 %) occurred with the highest frequency.
3.3 Treatment Costs
The total average cost per encounter in men w/BM and men
w/oBM was US$9,728 and US$7,405, respectively
(P = 0.0006) (Table 2). Room and board charges repre-
sented 38.9 % of the overall cost for men w/BM (US$3,788
per encounter). Room and board and higher pharmacy costs
(w/BM US$2,017 vs. w/oBM US$551) corresponded with a
greater average LOS in men w/BM. In contrast, surgery
(US$1,798), room and board (US$1,320), and radiation
(US$1,515) were the major cost contributors in men w/oBM.
Surgeries were not common in men w/BM in both
treatment settings; however, they were less frequent in the
outpatient setting. For men w/oBM, the most common
surgery was RP, for which the mean cost was US$3,714
across both settings (Table 3). Radiation procedures for
men w/oBM ranged from US$197 for radioelement han-
dling/loading to US$2,073 for external beam RT-related
procedures (Table 4). For men w/BM, the least costly
radiation procedure was also radioelement handling/load-
ing (average US$194) and the most costly procedure was
interstitial brachytherapy (average US$1,846 per proce-
dure). Radiopharmaceuticals ranged from US$306 for
isotope iridium seed to US$5,814 for isotope palladium
seed in men w/oBM (Table 5). Additionally, the vast
majority of radiopharmaceuticals were provided to men
w/oBM in the outpatient setting.
4 Discussion
In this analysis, we compared healthcare resource utiliza-
tion and costs associated with PCa w/BM versus w/oBM.
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Our primary variables of interest were treatments utilized
within the encounter, corresponding costs, and LOS.
Results showed that men w/BM were 1.5 times more likely
to be treated in an inpatient setting compared with men






Age in years (mean, SD) 69, 10 73, 10
Race
African American 11.8 % 15.8 %
Caucasian 65.7 % 62.0 %
Hispanic 2.7 % 4.3 %
Other 19.8 % 18.0 %
Treatment setting
Inpatient 39.7 % 57.8 %
Hospital-based outpatient 60.3 % 42.2 %
Payer type
Medicare 60.1 % 74.3 %
Medicaid 2.0 % 4.8 %
Commercial/private 33.5 % 15.7 %
Self-pay 1.2 % 2.1 %
Other 3.3 % 3.1 %
Region
Northeast 14.1 % 15.4 %
Midwest 22.7 % 20.3 %
South 43.3 % 45.6 %
West 20.0 % 18.8 %
Hospital type
Urban 85.2 % 84.5 %
Rural 14.8 % 15.6 %
Teaching 39.1 % 40.6 %
Non-teaching 60.9 % 59.4 %
Bed size
Average number of beds 433 425
0–200 10.9 % 11.9 %
201–400 41.3 % 39.6 %
401–600 28.2 % 32.1 %
601–1,000 17.0 % 14.8 %
[1,000 2.6 % 1.5 %
Admission source
Physician referral 76.7 % 51.5 %
Clinic referral 5.7 % 3.1 %
Transfer from a hospital 0.7 % 2.6 %
Transfer from another healthcare
facility
0.6 % 1.7 %
Emergency room 9.0 % 36.0 %
Other 7.4 % 5.0 %
Admission type
Emergency department 9.5 % 38.6 %
Urgent 5.1 % 12.4 %
Elective 73.4 % 40.9 %
Other 12.0 % 8.2 %
Primary admitting diagnosis

























Fig. 1 Treatment utilization by hospital encounter: inpatient stays
and outpatient visits. All comparisons were P \ 0.0001. *N represents
the number of hospitalizations among the sample of PCa patients
treated in an inpatient and/or outpatient setting and does not represent
the number of unique patients. PCa prostate cancer, w/BM with bone







factors influencing health status
and contact with health services
(V01–V91.9)
17.0 % 18.7 %
Secondary malignant neoplasm
of other specified sites (198.xx)
0.2 % 13.5 %
Diseases of the circulatory
system (390–459.9)
3.1 % 6.1 %
Diseases of the genitourinary
system (580–629.9)
2.7 % 5.2 %
Diseases of the respiratory
system (460–519.9)
2.2 % 4.5 %
Diseases of the digestive system
(520–579.9)
1.2 % 3.5 %
Injury and poisoning
(800–999.9)
1.2 % 2.6 %
Symptoms, signs, and ill-defined
conditions (780–799.9)
1.0 % 2.5 %
Other 8.4 % 19.5 %
PCa prostate cancer, w/BM with bone metastases, w/oBM without
bone metastases, SD standard deviation
(P value for all: \0.0001 except primary admitting diagnosis for
which no statistical comparisons were made)
* N represents the number of hospitalizations among the sample of
PCa patients treated in an inpatient and/or outpatient setting and does
not represent the number of unique patients
 Other primary admitting diagnoses include, but are not limited to,
diseases of the musculoskeletal system and connective tissue
(710–739.9), infectious and parasitic diseases (001–139.8), and dis-
eases of blood and blood-forming organs (280–289.9)
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w/oBM (57.8–39.7 %). These results underscore the med-
ical instability of men w/BM, which is also confirmed by
evaluating the nature of inpatient hospitalizations across
the two groups. When men w/oBM were hospitalized,
elective-type admissions were most common, indicating
that many procedures/visits were scheduled in advance and
patients were medically stable. Men w/BM were signifi-
cantly more likely to have emergency department or urgent
admissions, likely demonstrating lower disease stability.
This finding may have impacted the cost difference
between the two study groups, as costs associated with
inpatient encounters were significantly higher in men
w/BM. Almost 40 % of the total cost was due to a longer
LOS (4 additional days) and associated inpatient pharmacy
costs. The inpatient LOS across the entire cohort of men
was 4 days, similar to previous estimates [23].
When men w/oBM were admitted to the hospital, sur-
gery was the most common procedure, occurring in two out
of every three hospital stays. This finding is also consistent
with Milenkovic et al. [22], where the most common pro-
cedures were RPs and TURPs. In contrast, men w/BM
treated in the inpatient setting generally received primary/
secondary hormonal therapy. In the outpatient treatment
setting, men w/oBM were more likely to have RT, while
men w/BM were more likely to have chemotherapy. These
findings are consistent with the current treatment para-
digms for PCa [4, 17].
Studies on the economic burden of CRPC are limited,
particularly from a hospital perspective, so our study
sought to provide a more granular evaluation of these
services. Given changes in the treatment landscape with
CRPC, our primary interests were surgery, RT, chemo-
therapy, and radiopharmaceuticals. Prostatectomy proce-
dures were the most commonly occurring surgery (average
US$3,027), while docetaxel was the most prevalent che-
motherapy (average US$2,197). Radiation procedures,
particularly brachytherapy-related procedures (US$1,846),
were also more commonly seen in this group, with the
majority of procedures done in a hospital-based outpatient
setting. Additionally, the most common radiopharmaceu-
ticals administered at outpatient visits in men w/oBM were
iodine-125 and palladium, which contributed to high costs
of therapy in this setting. This finding was supported by the
literature, as these are common, permanent, low-dose rate
radiopharmaceuticals used in this population [1]. Radio-
pharmaceuticals are also an option for patients with mul-
tifocal bone pain, particularly if they are no longer
candidates for effective chemotherapy [18]. Unlike previ-
ous findings, 89Sr and 153Sm (b-emitting agents) were not
the two most commonly used radiopharmaceuticals in our
sample. Both can cause myelosuppression, limiting their
use in patients with compromised bone marrow reserves,
and may prevent future administration of chemotherapy.
Radium-223, an a-emitting radiopharmaceutical, targets
bone metastases with high-energy, short-range irradiation
[20]. This characteristic mechanism spares bone marrow as
a result of lower penetration to surrounding tissues and
limits toxic effects compared with traditional b-emitting
radiopharmaceuticals [20]. A phase III, randomized, dou-
ble-blind, placebo-controlled study (N = 921) evaluated
the efficacy and safety of radium-223. OS, the primary
endpoint, was significantly increased with radium-223
compared with placebo (14.9 vs. 11.3 months;
P = 0.00007). Time to first SRE, the key secondary end-
point, was significantly delayed (median time to SRE 12.2
vs. 6.7 months, respectively; P \ 0.0001) [23]. These
benefits may result in quick incorporation of radium-223
into clinical practice and guidelines for CRPC.
Although this assessment attempts to provide a granular
evaluation of common CRPC treatments utilized in the

























Fig. 2 Treatment utilization by hospital encounter: inpatient stays
only. All comparisons were P \ 0.0001, except for nuclear medicine
(P = 0.0164). *N represents the number of hospitalizations among
the sample of PCa patients treated in an inpatient setting and does not
represent the number of unique patients. PCa prostate cancer, w/BM

























Fig. 3 Treatment utilization by hospital encounter: outpatient visits
only. All comparisons were P \ 0.05. *N represents the number of
hospitalizations among the sample of PCa patients treated in an
outpatient setting and does not represent the number of unique
patients. PCa prostate cancer, w/BM with bone metastases, w/oBM
without bone metastases
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study as providing a baseline understanding of where future
patterns of care will be derived. Recently approved treat-
ments, such as abiraterone acetate, sipuleucel-T, enzaluta-
mide, denosumab, and cabazitaxel [4], as well as
radiopharmaceutical radium-223, are not captured in this
assessment. The recent entries of these products limit our
ability to evaluate their current utilization and costs. It will
be imperative for decision makers to understand the
incremental costs and benefits associated with these agents
as new treatment patterns emerge.
Although no cost information exists for radium-223
and enzalutamide, decision makers can assess the cost and
resulting cost effectiveness for these agents. On the basis
of survival gains in a PCa population and pricing for
individual treatments, docetaxel appears to be the most
cost effective agent, with sipuleucel-T being the least cost
effective [8, 11, 13]. The incremental survival benefit of
abiraterone, radium-223, enzalutamide, and sipuleucel-T
must be considered from a willingness-to-pay perspective;
thus, a net-benefit analysis or model should be conducted
once all information is available. Additionally, several
treatments (e.g., RT) may be decreased as a result of
these agents, which would offset product-specific costs.
This premise of cost offsets may be of extreme impor-
tance to medical decision makers. A recent study of men
with PCa indicated that the highest treatment cost was
observed in patients who initially had RT. On average,
their total costs were US$42,554, with half of these costs
due to outpatient resource utilization [24]. Our study
supports these findings as well, as RT was one of the
more common treatments evaluated within the context of
this paper.
A greater focus on the cost effectiveness of treatments
for PCa, both in the inpatient and outpatient settings, will
be an important consideration for healthcare decision
makers. As RT has been identified as a high-cost treatment,
it would be beneficial for medical decision makers to fur-
ther analyze ways to offset associated services and costs
Table 2 Treatment costs per encounter
Standard billing
department codes













Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Total costs (US$) $11,944 (13,245) $4,422 (7,127) $7,405
(10,666)




$233 (1,499) $59 (282) $128 (973) $281 (1,289) $146 (349) $224 (1,008)
Ambulance $4 (143) $0 (7) $1 (90) $8 (114) $0 (10) $5 (87)
Surgery $3,692 (3,691) $553 (1,514) $1,798 (3,024) $813 (1,868) $155 (842) $535 (1,556)
Audiology $0 (7) $0 (0) $0 (4) $0 (6) $0 (0) $0 (5)
Blood bank $202 (664) $4 (72) $83 (433) $466 (1,342) $34 (245) $284 (1,054)
Cardiology $124 (623) $17 (1,982) $60 (1,590) $149 (521) $7 (264) $89 (437)
Central supply $2,025 (3,484) $287 (2,204) $976 (2,910) $912 (3,463) $49 (578) $548 (2,692)
Diagnostic $287 (779) $245 (777) $262 (778) $933 (1,494) $71 (275) $569 (1,226)
Dialysis $34 (476) $0 (10) $14 (300) $67 (652) $0 (26) $39 (497)
Durable medical
equipment
$95 (697) $4 (74) $40 (445) $61 (538) $4 (196) $37 (429)
Emergency room $93 (224) $5 (68) $40 (157) $274 (309) $13 (92) $164 (275)
All home health $0 (36) $0 (32) $0 (34) $8 (873) $2 (90) $5 (666)
Laboratory $353 (3,668) $20 (70) $152 (2,317) $672 (862) $60 (120) $413 (726)
Nuclear medicine $50 (431) $421 (2,485) $274 (1,958) $134 (466) $96 (842) $118 (652)
Pathology $165 (234) $7 (60) $69 (173) $64 (229) $2 (45) $38 (179)
Pharmacy $894 (2,545) $326 (1,528) $551 (2,014) $1,760 (3,462) $2,369 (4,965) $2,017 (4,175)
Rehabilitation $125 (543) $1 (21) $50 (348) $332 (831) $3 (37) $193 (653)
Psychiatry $4 (568) $0 (4) $2 (357) $3 (175) $0 (10) $2 (133)
Radiation therapy $61 (2,477) $2,471 (5,354) $1,515 (4,596) $383 (2,318) $674 (1,895) $506 (2,154)
Respiratory therapy $176 (882) $1 (16) $70 (562) $266 (1,386) $2 (26) $154 (1,061)
Room and board $3,327 (6,297) $1 (49) $1,320 (4,287) $6,558 (9,251) $2 (65) $3,788 (7,740)
PCa prostate cancer, SD standard deviation, w/BM with bone metastases, w/oBM without bone metastases
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while maximizing patient survival and outcomes. With the
abundance of newer agents recently approved and in the
research pipeline, determining the most cost-effective
strategy through empirical research will be the primary
goal for all stakeholders, including patients.
5 Strengths and Limitations
This study has several strengths and limitations. First,
this was a retrospective hospital claims analysis, which
limits the amount of clinical information available (e.g.,
tumor stage, chief complaint), which would be valuable
to stratify treatments on the basis of relevant risk groups.
Additional detail or utilization occurring outside of this
setting is not available and may also be useful in further
describing the cohorts. Further studies investigating such
clinical information may provide information regarding
variables that drive admission between patients with
w/BM and w/oBM. Furthermore, the differences reported
here between these two cohorts (w/BM vs. w/oBM) may
not be fully attributable to bone metastases status because
of other differences between the two cohorts that may
not have been measured. Secondly, a common limitation
in studies such as ours that use an administrative
healthcare database is selecting claims on the basis of
ICD-9 codes. As such, there is potential for misclassifi-
cation of patients. However, our analysis included a total
of 211,440 encounters, which produced a good sample
for evaluation. The mean age was 73 years in men w/BM
and 69 years in men w/oBM in our study, which corre-
sponds well to the overall PCa population (mean age of
diagnosis for PCa is 67 years according to the most
recent Survival, Epidemiology, and End Results [SEER]
data) [3]. This similarity in demographics is thought to
give our analysis good generalizability to the overall PCa
population. However, two-thirds of the encounters in our
study were in Caucasian men, while African American
men represented approximately 10 % of patients. Previ-
ous studies have demonstrated that PCa disproportion-
ately affects African American men and, worldwide,
African American men have the highest incidence of PCa
[25, 26]. Therefore, the difference in racial demographics
in our population compared with the general PCa popu-
lation could be considered a limitation. The majority of
men in our analysis were treated in urban non-teaching
hospitals, whereas CRPC patients are generally referred
to teaching hospitals or cancer treatment centers. Hence,
our sample may not be fully representative of the clinical
practices of PCa, as most hospitals participating in the
Premier Perspective Database are predominantly small- to
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6 Conclusions
Costs and utilization of PCa-related treatments vary on the
basis of the presence of metastases and treatment setting
(inpatient vs. outpatient). As new treatment patterns in PCa
evolve, decision makers and clinicians will continue to pay
close attention to utilization of healthcare resources. Our
study provides detailed information on utilization of
healthcare resources in patients with PCa from a nationally
representative hospital database to help inform the con-
versation about healthcare resource utilization and emerg-
ing treatment patterns.
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